1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.1. Qualitative Research
2.1.1. Primary & Secondary Sources

2.2. Quantitative Research
2.2.1. Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.4. Assumption for the Study

2.5. Market Size Estimation

2.6. Data Triangulation

Executive Summary: Global Pharmaceutical Manufacturing Market 

4.1. Industry Value Chain Analysis
4.1.1. Material Provider
4.1.2. Manufacturer
4.1.3. Distributor
4.1.4. End User

4.2. Industry Outlook
4.2.1. Global Trade of Pharmaceutical Products, 2023
4.2.2. Number of Deaths by Cause, 2023

4.3. PESTLE Analysis

4.4. Porter's Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition

4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.2. Restraints
4.5.3. Challenges
4.5.4. Key Trends

4.6. Covid-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
4.7.1. Market Revenue Estimates and Forecast (US$ Bn), 2019 - 2032
4.7.2. Market Volume Estimates and Forecast (MT), 2019 - 2032
4.7.3. Price Trend Analysis, By Drug Type

4.8. Competition Dashboard
4.8.1. Market Concentration Rate
4.8.2. Company Market Share Analysis (Value %), 2023
4.8.3. Competitor Mapping 

5.1. Key Insights

5.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
5.2.1. Branded Prescription Drugs
5.2.2. Generic Prescription Drugs
5.2.3. Over-The Counter Drugs (OTC)

6.1. Key Insights

6.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
6.2.1. Tablets
6.2.2. Capsules 
6.2.3. Injectables 
6.2.4. Sprays 
6.2.5. Suspensions 
6.2.6. Powder
6.2.7. Other Formulations

7.1. Key Insights

7.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
7.2.1. Oral Medicine 
7.2.2. Topical Medicine 
7.2.3. Parenteral Medicine
7.2.4. Inhalations
7.2.5. Other Routes of Administration

8.1. Key Insights

8.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
8.2.1. Cardiovascular Disease
8.2.2. Pain
8.2.3. Disease 
8.2.4. Cancer 
8.2.5. Respiratory Diseases 
8.2.6. Neurological Diseases 
8.2.7. Orthopedics 
8.2.8. Other Therapeutic Application

9.1. Key Insights

9.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
9.2.1. In- House Facility 
9.2.2. Outsourced facility 

10.1. Key Insights

10.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
10.2.1. Retail Channel
10.2.2. Non-retail
10.2.3. Online Channel

11.1. Key Insights

11.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
11.2.1. North America
11.2.1.1. The U.S.
11.2.1.2. Canada
11.2.1.3. Mexico
11.2.2. Europe
11.2.2.1. Western Europe
11.2.2.1.1. The UK
11.2.2.1.2. Germany
11.2.2.1.3. France
11.2.2.1.4. Italy
11.2.2.1.5. Spain
11.2.2.1.6. Rest of Western Europe
11.2.2.2. Eastern Europe
11.2.2.2.1. Poland 
11.2.2.2.2. Russia
11.2.2.2.3. Rest of Eastern Europe
11.2.3. Asia Pacific
11.2.3.1. China
11.2.3.2. India
11.2.3.3. Japan
11.2.3.4. South Korea
11.2.3.5. Australia & New Zealand
11.2.3.6. ASEAN
11.2.3.7. Rest of Asia Pacific
11.2.4. Middle East & Africa
11.2.4.1. UAE
11.2.4.2. Saudi Arabia
11.2.4.3. South Africa
11.2.4.4. Rest of MEA
11.2.5. South America
11.2.5.1. Argentina
11.2.5.2. Brazil
11.2.5.3. Rest of South America

12.1. Key Insights

12.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
12.2.1. By Drug Type 
12.2.2. By Formulation
12.2.3. By Route of Administration 
12.2.4. By Therapeutic Application
12.2.5. By Manufacturing Facility 
12.2.6. By Distribution Channel 
12.2.7. By Country 

13.1. Key Insights

13.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
13.2.1. By Drug Type 
13.2.2. By Formulation
13.2.3. By Route of Administration 
13.2.4. By Therapeutic Application
13.2.5. By Manufacturing Facility 
13.2.6. By Distribution Channel 
13.2.7. By Country

14.1. Key Insights

14.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
14.2.1. By Drug Type 
14.2.2. By Formulation
14.2.3. By Route of Administration 
14.2.4. By Therapeutic Application
14.2.5. By Manufacturing Facility 
14.2.6. By Distribution Channel 
14.2.7. By Country

15.1. Key Insights

15.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
15.2.1. By Drug Type 
15.2.2. By Formulation
15.2.3. By Route of Administration 
15.2.4. By Therapeutic Application
15.2.5. By Manufacturing Facility 
15.2.6. By Distribution Channel 
15.2.7. By Country

16.1. Key Insights

16.2. Market Size and Forecast, 2019 - 2032 (US$ Bn and MT)
16.2.1. By Drug Type 
16.2.2. By Formulation
16.2.3. By Route of Administration 
16.2.4. By Therapeutic Application
16.2.5. By Manufacturing Facility 
16.2.6. By Distribution Channel 
16.2.7. By Country

17.1. Abbott Laboratories
17.2. AbbVie Inc.
17.3. ACADIA Pharma
17.4. Aenova Group
17.5. Amgen Inc
17.6. AstraZeneca plc
17.7. Bayer AG
17.8. Biogen Inc
17.9. Boehringer Ingelheim International GmbH
17.10. Eli Lilly and Company
17.11. F. Hoffmann-La Roche AG
17.12. GSK plc
17.13. Merck KGaA
17.14. Novartis AG
17.15. Novo Nordisk A/S
17.16. Pfizer Inc
17.17. Sanofi SA
17.18. Other Prominent Players